Innovator’s Pitch Challenge

Drusolv Therapeutics
Ocustatin™ for Treatment of Intermediate AMD

John Edwards, Founder & CEO, Drusolv Therapeutics
jedwards@drusolv.com

Message the company or request a 1:1 meeting here.

Vote for Winner

Drusolv Therapeutics is a clinical-stage drug company based in Philadelphia. We are developing a high-dose oral statin for early intervention in a blinding eye disease called age-related macular degeneration (AMD). Our product, Ocustatin™, is aimed at patients who are still in the intermediate stages of the disease and currently have very limited options to prevent progression to late-stage vision loss. This is a $4B per year, completely unmet need.

Slide Deck

Pitch Video

Executive Summary